BX-004 is under clinical development by BiomX and currently in Phase II for Resistant Pseudomonas aeruginosa Infections. According to GlobalData, Phase II drugs for Resistant Pseudomonas aeruginosa Infections does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the BX-004 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BX-004 overview
BX-004 is under development for the treatment of cystic fibrosis, non-cystic fibrosis bronchiectasis and resistant pseudomonas aeruginosa infections. It is administered as inhalational formulation. The drug candidate comprises of cocktail of natural phages developed based on BOLT (Bacteriophage Lead to Treatment) platform.
BiomX overview
BiomX is a microbiome company that develops natural and engineered phage cocktails targeting harmful bacteria in chronic diseases and conditions such as cystic fibrosis and diabetic foot osteomyelitis. The company’s pipeline products include BX004 to treat cystic fibrosis (CF) and BX211 for the treatment of diabetic foot osteomyelitis (DFO). It utilizes its proprietary BOLT platform to develop phage-based product candidates. It works in collaboration with Janssen Pharmaceuticals, Boehringer Ingelheim, and Maruho Co. Ltd. BiomX is headquartered in Ness Ziona, Israel.
For a complete picture of BX-004’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
